Bu Shang Pharmaceutical: Subsidiary drugs are planned to be selected for continuation of procurement.

By-Health Pharmaceutical announced that the national centralized procurement drug agreement period for the subsidiary Shaanxi Busheli High-Tech Pharmaceutical Co., Ltd., Shaanxi Busheli Pharmaceutical Co., Ltd., Shandong Danhong Pharmaceutical Co., Ltd., and the holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd. has expired and the selected products are planned to be purchased. Some products from the subsidiary are planned to be selected for this continuation procurement, with a procurement period from the actual date of selection result execution to December 31, 2028. The planned selected products include amlodipine besylate tablets, rivaroxaban tablets, metoprolol tartrate tablets, lacidipine tablets, pregabalin capsules, and torasemide injection.